Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients

• Published in: Journal of thrombosis and thrombolysis Vol. 50; no. 3; pp. 580 - 586
• Main Authors: Zhang, Yan, Cao, Wei, Jiang, Wei, Xiao, Meng, Li, Yongzhe, Tang, Ning, Liu, Zhengyin, Yan, Xiaowei, Zhao, Yongqiang, Li, Taisheng, Zhu, Tienan
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.10.2020
• Subjects: Aged; Antibodies, Antiphospholipid - blood; Antithrombin Proteins - analysis; Betacoronavirus - pathogenicity; Biomarkers - blood; Blood Coagulation; Blood Coagulation Factor Inhibitors - blood; Blood Coagulation Factors - analysis; Cardiology; China; Coronavirus Infections - blood; Coronavirus Infections - diagnosis; Coronavirus Infections - virology; COVID-19; Critical Illness; Cross-Sectional Studies; Female; Fibrin Fibrinogen Degradation Products - analysis; Hematology; Host-Pathogen Interactions; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Pandemics; Pneumonia, Viral - blood; Pneumonia, Viral - diagnosis; Pneumonia, Viral - virology; Protein C - analysis; Protein S - analysis; Risk Factors; SARS-CoV-2; Thrombosis - blood; Thrombosis - diagnosis; Thrombosis - virology; China; COVID-19; Critical; Antiphospholipid antibody; Coagulopathy; Factor VIII

The outbreak of novel coronavirus disease 2019 (COVID-19) has now become a global pandemic. Coagulopathy has been reported widely in critically ill COVID-19 patients and was related to high mortality. However, the comprehensive coagulation profiles have not been examined and the underlying mechanism...